Mitchell Sokoloff to Combined Modality Therapy
This is a "connection" page, showing publications Mitchell Sokoloff has written about Combined Modality Therapy.
Connection Strength
0.297
-
Berry DL, Hong F, Blonquist TM, Halpenny B, Xiong N, Filson CP, Master VA, Sanda MG, Chang P, Chien GW, Jones RA, Krupski TL, Wolpin S, Wilson L, Hayes JH, Trinh QD, Sokoloff M. Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. Urol Oncol. 2021 08; 39(8):493.e9-493.e15.
Score: 0.165
-
Katz EE, Suzue K, Wille MA, Krausz T, Rapp DE, Sokoloff MH. Primary malignant melanoma of the urethra. Urology. 2005 Feb; 65(2):389.
Score: 0.055
-
Sokoloff MH, Chung LW. Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis Rev. 1998-1999; 17(4):307-15.
Score: 0.033
-
Sokoloff MH, deKernion JB, Figlin RA, Belldegrun A. Current management of renal cell carcinoma. CA Cancer J Clin. 1996 Sep-Oct; 46(5):284-302.
Score: 0.031
-
Yang XJ, Sugimura J, Tretiakova MS, Furge K, Zagaja G, Sokoloff M, Pins M, Bergan R, Grignon DJ, Stadler WM, Vogelzang NJ, Teh BT. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer. 2004 Mar 01; 100(5):976-85.
Score: 0.013